| abstract |
The present invention relates to a composition comprising an inhibitor of plexin-B1 and an inhibitor of plexin-B2, wherein the inhibitor of plexin-B1 and/or the inhibitor of plexin-B2 is/are preferably selected from (i) an inhibitor of the nucleic acid molecule encoding plexin-B1 and/or plexin-B2 selected from a small molecule, an aptamer, a siRNA, a shRNA, a miRNA, a morpholino, a ribozyme, an antisense nucleic acid molecule, a CRISPR-Cas9-based construct, a CRISPR-Cpf1 -based construct, a meganuclease, a zinc finger nuclease, and a transcription activator-like (TAL) effector (TALE) nuclease, and/or (ii) an inhibitor of the plexin-B1 and/or plexin-B2 protein selected from a small molecule, an antibody or antibody mimetic, an aptamer, wherein the antibody mimetic is preferably selected from affibodies, adnectins, anticalins, DARPins, avimers, nanofitins, affilins, Kunitz domain peptides and Fynomers®. |